Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
Objective Analysis of etanercept biosimilars in pediatric patients with juvenile idiopathic arthritis (JIA) in comparison with the etanercept originator in terms of efficacy and safety. Methods Patients diagnosed with JIA who started treatment with either the etanercept originator or a biosimilar af...
Guardado en:
Autores principales: | Franz Thiele, Ariane Klein, Anton Hospach, Daniel Windschall, Sonja Mrusek, J. Michael Ruehlmann, Gerd Horneff |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1b438a336af34b0da53e55d8912c6ed0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz J, et al.
Publicado: (2015) -
Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis EM, et al.
Publicado: (2014) -
Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
por: Michihito Sato, et al.
Publicado: (2011) -
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami M, et al.
Publicado: (2012) -
Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: Safety, efficacy, and features affecting outcome. A comprehensive review of the literature
por: Alisa Carman Gotte
Publicado: (2009)